The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

If you continue to have this issue please contact customerservice@slackinc.com. More than 80% of Omvoh responders from the VIVID-1 study maintained endoscopic response at week 104 in VIVID-2.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

and the approval of Omvoh for treating moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY) declared a 15.4% hike in its quarterly dividend in December 2024 to $1.50 ...

Most patients on Lilly's Omvoh ® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years "These positive, multi-year data can give health ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

INDIANAPOLIS—Lilly Endowment Inc., een belangrijke aandeelhouder in Eli Lilly & Co. (NYSE: LLY ), heeft onlangs een ...

In terms of product development, Eli Lilly reported that its drug Omvoh has shown sustained efficacy in Crohn's disease patients over two years of continuous treatment. This promising development ...

UPDATED: Thursday, Jan. 16 at 10:25 a.m. ET Eli Lilly's Omvoh has picked up its second major FDA nod. After the IL-23 inhibitor's approval in 2023 to treat ulcerative colitis, the agency has now ...